ClinicalTrials.Veeva

Menu
M

Mississippi Retina Associates | Jackson, MS

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Faricimab
Ranibizumab
OCU410ST
AVD-104
Dexamethasone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 8 total trials

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (SIGLEC)

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects....

Active, not recruiting
Stargardt Disease
Drug: OCU410ST

ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of ne...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Genetic: ABBV-RGX-314 Dose 1
Biological: Aflibercept (EYLEA®)

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD)....

Active, not recruiting
Geographic Atrophy
Genetic: OCU410

This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.

Active, not recruiting
Diabetic Macular Edema
Drug: Faricimab

Trial sponsors

Ocugen logo
AbbVie logo
A
H
McMaster University logo
O
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems